Analysts Anticipate Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.15 EPS

Equities research analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will announce earnings per share (EPS) of ($0.15) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Achillion Pharmaceuticals’ earnings, with estimates ranging from ($0.15) to ($0.14). Achillion Pharmaceuticals posted earnings of ($0.17) per share during the same quarter last year, which suggests a positive year over year growth rate of 11.8%. The firm is expected to announce its next earnings results on Thursday, February 28th.

According to Zacks, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.53) per share for the current financial year, with EPS estimates ranging from ($0.53) to ($0.52). For the next financial year, analysts expect that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.71) to ($0.66). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02.

A number of equities analysts have issued reports on ACHN shares. BidaskClub cut shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 18th. ValuEngine cut shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, December 18th. Finally, Zacks Investment Research cut shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company. Achillion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.17.

A number of institutional investors and hedge funds have recently bought and sold shares of ACHN. Point72 Asset Management L.P. acquired a new stake in shares of Achillion Pharmaceuticals during the third quarter worth $6,609,000. Nexthera Capital LP acquired a new stake in Achillion Pharmaceuticals in the 3rd quarter valued at $5,829,000. Assenagon Asset Management S.A. acquired a new stake in Achillion Pharmaceuticals in the 3rd quarter valued at $5,100,000. Dimensional Fund Advisors LP increased its stake in Achillion Pharmaceuticals by 14.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,892,184 shares of the biopharmaceutical company’s stock valued at $19,505,000 after buying an additional 849,721 shares during the last quarter. Finally, Marshall Wace North America L.P. increased its stake in Achillion Pharmaceuticals by 464.9% in the 3rd quarter. Marshall Wace North America L.P. now owns 820,146 shares of the biopharmaceutical company’s stock valued at $3,018,000 after buying an additional 674,956 shares during the last quarter. Institutional investors own 77.12% of the company’s stock.

ACHN stock traded up $0.02 during midday trading on Wednesday, reaching $2.14. The company’s stock had a trading volume of 36,714 shares, compared to its average volume of 3,025,738. Achillion Pharmaceuticals has a 52 week low of $1.29 and a 52 week high of $4.34. The stock has a market cap of $285.55 million, a PE ratio of -3.47 and a beta of 2.11.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Read More: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply